The funding will help expedite the development of a novel non-surgical heart valve for young children with congenital heart disease. Credit: Anatta_Tan / Shutterstock.com.

PolyVascular is set to receive strategic support, resources and $2m in funding from CobiCure Medical Technologies (CobiCure MedTech) to expedite the development of a non-surgical heart valve for young children with congenital heart disease.

PolyVascular’s polymer heart valve is anticipated to become the first of its kind to show readiness for human clinical use.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This valve uses a novel polymer for the replacement of faulty heart valves, decreasing the need for multiple surgeries and enhancing patients’ quality of life.

Congenital heart defects affect almost 40,000 births annually, as reported by the US Centers for Disease Control and Prevention.

PolyVascular founder and paediatric cardiologist Henri Justino said: “This investment from CobiCure MedTech is a testament to the progress our team has made and acknowledges the need for better solutions for children with congenital heart disease.”

See Also:

The latest funding adds to the $3.5m in grants earlier received from the National Institutes of Health and Small Business Innovation Research Phase I and Phase II, along with private funding of $750,000.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CobiCure MedTech strategy and development director Emma Moran said: “CobiCure’s mission, strategic ecosystem, and critical resources are a perfect match for helping PolyVascular realise their goal of eliminating invasive surgeries in children with congenital heart disease.

“Our commitment to supporting life-changing medical devices like PolyVascular’s will fill gaps in paediatric MedTech and we look forward to the positive impact it could have on children’s lives.”